$Fruquintinib for Refractory Metastatic CRC, Abortion Facility Type and Procedural Complications, Screening for Osteoporosis, and more$

JAMA Editor’s Summary

Fruquintinib for Refractory Metastatic CRC, Abortion Facility Type and Procedural Complications, Screening for Osteoporosis, and more

Editor's Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the

June 26, 2018

Listen on your favorite player Take me to this show’s page

Newer →

HPV vs Pap Smear Screening for Cervical Cancer, Basal vs NPH Insulin For Type 2 Diabetes, Management of Infective Endocarditis, and more

← Older

Optimal Target HbA1c, Genetic Risks for Pancreatic Cancer, US Trends in Obesity, and more

Facebook Twitter Buffer LinkedIn WhatsApp

Fruquintinib for Refractory Metastatic CRC, Abortion Facility Type and Procedural Complications, Screening for Osteoporosis, and more

Editor’s Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the June 26, 2018 issue

Listen on your favorite player

New to Podcasts? It's easy to get started!

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

We gratefully acknowledge the many organizations that have generously supported our podcasts and platform.

Network Sponsors and Advertisers

Event and Media Partners

00:00

00:00